NTLA Stock Overview
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Intellia Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.34 |
| 52 Week High | US$47.48 |
| 52 Week Low | US$21.18 |
| Beta | 1.8 |
| 1 Month Change | -22.77% |
| 3 Month Change | -16.48% |
| 1 Year Change | -40.32% |
| 3 Year Change | -71.39% |
| 5 Year Change | 27.10% |
| Change since IPO | -3.44% |
Recent News & Updates
Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24
Recent updates
Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price
Oct 11Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Aug 31Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation
Aug 01Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Jul 05Intellia Makes History. Can It Deliver A Cure?
Jun 28Intellia Therapeutics Q1 2021 Earnings Preview
May 05Intellia Expands Its In Vivo Advantage
May 02Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth
Apr 16Broker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher
Mar 12Shareholder Returns
| NTLA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.7% | -4.7% | -3.7% |
| 1Y | -40.3% | -2.7% | 20.2% |
Return vs Industry: NTLA underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: NTLA underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| NTLA volatility | |
|---|---|
| NTLA Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTLA's share price has been volatile over the past 3 months.
Volatility Over Time: NTLA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 526 | John Leonard | www.intelliatx.com |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.
Intellia Therapeutics, Inc. Fundamentals Summary
| NTLA fundamental statistics | |
|---|---|
| Market cap | US$2.06b |
| Earnings (TTM) | -US$481.19m |
| Revenue (TTM) | US$36.28m |
56.7x
P/S Ratio-4.3x
P/E RatioIs NTLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTLA income statement (TTM) | |
|---|---|
| Revenue | US$36.28m |
| Cost of Revenue | US$435.07m |
| Gross Profit | -US$398.79m |
| Other Expenses | US$82.40m |
| Earnings | -US$481.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.99 |
| Gross Margin | -1,099.36% |
| Net Profit Margin | -1,326.51% |
| Debt/Equity Ratio | 0% |
How did NTLA perform over the long term?
See historical performance and comparison